Connect your AI

Vaxcyte, Inc. PCVX Change in Other Assets

Change in Other Assets at other companies

PfizerPFE

-$322.25M+61.9%

ModernaMRNA

-$54M-17.4%

Krystal Biotech, Inc.KRYS

$1.7M-50.5%

ImmunityBio, Inc.IBRX

$1.05M+1,152%

Other financials

Income statement

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

Market cap$7.43B+72.0%

Enterprise value$7.28B+78.6%

Returns & leverage

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vaxcyte, Inc.'s change in other assets?: Vaxcyte, Inc. (PCVX) reported change in other assets of $8.74M in Q1 2026.
How has Vaxcyte, Inc.'s change in other assets changed year-over-year?: Vaxcyte, Inc.'s change in other assets increased by 483.3% year-over-year, from $1.5M to $8.74M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.